Olivier Rascol

53.3k total citations · 8 hit papers
434 papers, 27.5k citations indexed

About

Olivier Rascol is a scholar working on Neurology, Cellular and Molecular Neuroscience and Cognitive Neuroscience. According to data from OpenAlex, Olivier Rascol has authored 434 papers receiving a total of 27.5k indexed citations (citations by other indexed papers that have themselves been cited), including 342 papers in Neurology, 89 papers in Cellular and Molecular Neuroscience and 61 papers in Cognitive Neuroscience. Recurrent topics in Olivier Rascol's work include Parkinson's Disease Mechanisms and Treatments (322 papers), Neurological disorders and treatments (234 papers) and Botulinum Toxin and Related Neurological Disorders (82 papers). Olivier Rascol is often cited by papers focused on Parkinson's Disease Mechanisms and Treatments (322 papers), Neurological disorders and treatments (234 papers) and Botulinum Toxin and Related Neurological Disorders (82 papers). Olivier Rascol collaborates with scholars based in France, United States and Austria. Olivier Rascol's co-authors include Werner Poewe, Christopher G. Goetz, Cristina Sampaio, Anthony E. Lang, Eduardo Tolosa, Santiago Perez‐Lloret, David J. Brooks, Jean‐Louis Montastruc, Fabrizio Stocchi and Robert A. Hauser and has published in prestigious journals such as New England Journal of Medicine, The Lancet and SHILAP Revista de lepidopterología.

In The Last Decade

Olivier Rascol

425 papers receiving 26.7k citations

Hit Papers

Movement Disorder Society... 2000 2026 2008 2017 2004 2000 2011 2003 2009 500 1000 1.5k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Movement Disorder Society Task Force report on the Hoehn and Yahr staging scale: Status and recommendations The Movement Disorder Society Task Force on rating scales for Parkinson's disease
    2004 1.8k citations Christopher G. Goetz, Werner Poewe et al. Movement Disorders profile →
  2. A Five-Year Study of the Incidence of Dyskinesia in Patients with Early Parkinson's Disease Who Were Treated with Ropinirole or Levodopa
    2000 1.1k citations Olivier Rascol et al. profile →
  3. The Movement Disorder Society Evidence‐Based Medicine Review Update: Treatments for the non‐motor symptoms of Parkinson's disease
    2011 866 citations Klaus Seppi, Daniel Weintraub et al. Movement Disorders profile →
  4. Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL‐PET study
    2003 604 citations Olivier Rascol, Werner Poewe et al. profile →
  5. A Double-Blind, Delayed-Start Trial of Rasagiline in Parkinson's Disease
    2009 587 citations C. Warren Olanow, Olivier Rascol et al. profile →
  6. Depression rating scales in Parkinson's disease: Critique and recommendations
    2007 521 citations Anette Schrag, Paolo Barone et al. Movement Disorders profile →
  7. The Movement Disorder Society Evidence‐Based Medicine Review Update: Treatments for the motor symptoms of Parkinson's disease
    2011 387 citations Klaus Seppi, Werner Poewe et al. Movement Disorders profile →
  8. LRRK2 in Parkinson disease: challenges of clinical trials
    2020 301 citations Eduardo Tolosa, Olivier Rascol et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Olivier Rascol France 86 20.8k 7.7k 4.7k 3.0k 2.7k 434 27.5k
Wolfgang H. Oertel Germany 71 15.9k 0.8× 6.0k 0.8× 3.6k 0.8× 3.1k 1.1× 2.2k 0.8× 292 23.4k
Michael S. Okun United States 75 20.6k 1.0× 8.8k 1.2× 4.7k 1.0× 3.7k 1.2× 3.1k 1.1× 719 29.8k
José Á. Obeso Spain 78 21.1k 1.0× 10.8k 1.4× 5.3k 1.1× 3.8k 1.3× 1.9k 0.7× 308 29.1k
Eduardo Tolosa Spain 84 19.8k 1.0× 6.5k 0.8× 4.7k 1.0× 3.6k 1.2× 2.9k 1.0× 386 26.6k
Charles H. Adler United States 73 19.5k 0.9× 5.3k 0.7× 4.3k 0.9× 2.9k 1.0× 3.4k 1.2× 313 25.7k
Anette Schrag United Kingdom 71 16.6k 0.8× 4.5k 0.6× 3.1k 0.7× 2.4k 0.8× 3.3k 1.2× 308 22.4k
Klaus Seppi Austria 70 16.3k 0.8× 6.0k 0.8× 2.7k 0.6× 2.6k 0.9× 1.9k 0.7× 296 21.1k
Caroline M. Tanner United States 73 16.5k 0.8× 5.7k 0.7× 2.4k 0.5× 2.9k 1.0× 2.0k 0.7× 254 24.0k
Angelo Antonini Italy 78 15.8k 0.8× 5.4k 0.7× 3.5k 0.7× 1.8k 0.6× 2.0k 0.7× 529 21.0k
Christopher G. Goetz United States 96 27.4k 1.3× 8.6k 1.1× 6.9k 1.5× 3.3k 1.1× 5.7k 2.1× 431 36.6k

Countries citing papers authored by Olivier Rascol

Since Specialization
Citations

This map shows the geographic impact of Olivier Rascol's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Olivier Rascol with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Olivier Rascol more than expected).

Fields of papers citing papers by Olivier Rascol

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Olivier Rascol. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Olivier Rascol. The network helps show where Olivier Rascol may publish in the future.

Co-authorship network of co-authors of Olivier Rascol

This figure shows the co-authorship network connecting the top 25 collaborators of Olivier Rascol. A scholar is included among the top collaborators of Olivier Rascol based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Olivier Rascol. Olivier Rascol is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Kawabata, Kazuya, Florian Krismer, Mizuki Ito, et al.. (2025). Trajectories of Pontine Volume in Patients with Multiple System Atrophy. Movement Disorders. 40(7). 1369–1378. 1 indexed citations
2.
Dias, Sofia B., Beatriz da Costa Aguiar Alves, Olivier Rascol, et al.. (2025). AI-Driven Motor and Cognitive Decline Digital Assessment for Parkinson's Disease: A Systematic Review and Meta-Analysis. SSRN Electronic Journal. 1 indexed citations
3.
Bastos, Paulo, Christine Brefel‐Courbon, Isabelle Bénatru, et al.. (2025). Subcutaneous Apomorphine Infusion Initiation Is Associated with Impulse Control Disorder Attenuation in Advanced Parkinson's Disease Patients: Insights from the French NS ‐Park Cohort. Movement Disorders Clinical Practice. 13(1). 142–153. 2 indexed citations
4.
Artusi, Carlo Alberto, Silvia Gallo, Domiziana Rinaldi, et al.. (2024). Subthalamic and nigral stimulation for freezing of gait in Parkinson's disease: Randomized pilot trial. Journal of Parkinson s Disease. 14(8). 1602–1613.
5.
Pineda‐Pardo, José A., Raúl Martínez‐Fernández, Elena Natera‐Villalba, et al.. (2024). Skull Density Ratio as Arm‐Allocation Parameter for a Controlled Focused Ultrasound Trial in Parkinson's Disease. Movement Disorders Clinical Practice. 11(7). 825–829.
6.
Fabbri, Margherita, Olivier Rascol, Thomas Foltynie, et al.. (2024). Advantages and Challenges of Platform Trials for Disease Modifying Therapies in Parkinson's Disease. Movement Disorders. 39(9). 1468–1477. 8 indexed citations
7.
Lees, Andrew J., Eduardo Tolosa, Fabrizio Stocchi, et al.. (2023). Optimizing levodopa therapy, when and how? Perspectives on the importance of delivery and the potential for an early combination approach. Expert Review of Neurotherapeutics. 23(1). 15–24. 25 indexed citations
8.
Fabbri, Margherita, Raquel Barbosa, & Olivier Rascol. (2023). Off-time Treatment Options for Parkinson’s Disease. Neurology and Therapy. 12(2). 391–424. 28 indexed citations
9.
Rascol, Olivier, et al.. (2021). Opicapone for Parkinson’s Disease: Clinical Evidence and Future Perspectives. Neurodegenerative Disease Management. 11(3). 193–206. 1 indexed citations
10.
Fabbri, Margherita, Guillaume Baille, Matthieu Béreau, et al.. (2021). A French survey on the lockdown consequences of COVID-19 pandemic in Parkinson's disease. The ERCOPARK study. Parkinsonism & Related Disorders. 89. 128–133. 19 indexed citations
11.
Campo, Natalia del, Owen R. Phillips, Christine Brefel‐Courbon, et al.. (2020). Broad white matter impairment in multiple system atrophy. Human Brain Mapping. 42(2). 357–366. 20 indexed citations
12.
Moreau, Caroline, James A. Duce, Olivier Rascol, et al.. (2018). Iron as a therapeutic target for Parkinson's disease. Movement Disorders. 33(4). 568–574. 101 indexed citations
13.
Rascol, Olivier, Jean‐Christophe Corvol, Luc Defebvre, et al.. (2017). New perspectives on study designs for evaluating neuroprotection in Parkinson's disease. Movement Disorders. 32(10). 1365–1370. 11 indexed citations
14.
Tison, François, Charlotte Keywood, Franck Durif, et al.. (2016). A Phase 2A Trial of the Novel mGluR5‐Negative Allosteric Modulator Dipraglurant for Levodopa‐Induced Dyskinesia in Parkinson's Disease. Movement Disorders. 31(9). 1373–1380. 117 indexed citations
15.
Rascol, Olivier, Paolo Barone, Madhuri Behari, et al.. (2012). Perampanel in Parkinson Disease Fluctuations. Clinical Neuropharmacology. 35(1). 15–20. 45 indexed citations
16.
Péran, Patrice, Andrea Cherubini, Francesca Assogna, et al.. (2010). Magnetic resonance imaging markers of Parkinson’s disease nigrostriatal signature. Brain. 133(11). 3423–3433. 317 indexed citations
17.
Rascol, Olivier, Jean‐Philippe Azulay, Olivier Blin, et al.. (2010). Orodispersible sublingual piribedil to abort OFF episodes: A single dose placebo‐controlled, randomized, double‐blind, cross‐over study. Movement Disorders. 25(3). 368–376. 21 indexed citations
18.
Rascol, Olivier. (2008). Thérapeutiques du stade précoce de la maladie de Parkinson.. Revue Neurologique. 164(4). 329–49.
19.
Schrag, Anette, Paolo Barone, Richard G. Brown, et al.. (2007). Depression rating scales in Parkinson's disease: Critique and recommendations. Movement Disorders. 22(8). 1077–1092. 521 indexed citations breakdown →
20.
Giladi, Nir, Olivier Rascol, Daniel J. Brooks, et al.. (2004). Rasagiline treatment can improve freezing of gait in advanced Parkinson's disease; a prospective randomised double blind, placebo and entacapone controlled study.. Movement Disorders. 19. 17 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Wolfgang H. Oertel Breakdown of academic impact, for papers by Michael S. Okun Breakdown of academic impact, for papers by José Á. Obeso Breakdown of academic impact, for papers by Eduardo Tolosa Breakdown of academic impact, for papers by Charles H. Adler Breakdown of academic impact, for papers by Anette Schrag Breakdown of academic impact, for papers by Klaus Seppi Breakdown of academic impact, for papers by Caroline M. Tanner Breakdown of academic impact, for papers by Angelo Antonini Breakdown of academic impact, for papers by Christopher G. Goetz
Rankless by CCL
2026